Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.51 Insider Own30.19% Shs Outstand290.82M Perf Week4.12%
Market Cap1.48B Forward P/E- EPS next Y-0.53 Insider Trans0.00% Shs Float204.38M Perf Month-4.36%
Income-146.40M PEG- EPS next Q-0.13 Inst Own38.38% Short Float11.16% Perf Quarter6.77%
Sales38.03M P/S38.88 EPS this Y-2.05% Inst Trans11.15% Short Ratio14.42 Perf Half Y-10.78%
Book/sh3.96 P/B1.27 EPS next Y-0.87% ROA-9.67% Short Interest22.81M Perf Year-39.88%
Cash/sh2.69 P/C1.88 EPS next 5Y10.00% ROE-12.27% 52W Range3.87 - 8.48 Perf YTD-11.56%
Dividend Est.- P/FCF- EPS past 5Y- ROI-11.97% 52W High-40.48% Beta0.38
Dividend TTM- Quick Ratio7.32 Sales past 5Y477.63% Gross Margin- 52W Low30.49% ATR (14)0.27
Dividend Ex-Date- Current Ratio7.33 EPS Y/Y TTM-190.57% Oper. Margin-623.80% RSI (14)47.46 Volatility4.38% 5.10%
Employees586 Debt/Eq0.07 Sales Y/Y TTM-92.17% Profit Margin-384.99% Recom1.00 Target Price14.75
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q-56.05% Payout0.00% Rel Volume1.75 Prev Close5.08
Sales Surprise3.45% EPS Surprise-39.25% Sales Q/Q-57.40% EarningsFeb 20 AMC Avg Volume1.58M Price5.05
SMA20-0.87% SMA50-5.78% SMA200-9.70% Trades Volume2,766,861 Change-0.59%
Date Action Analyst Rating Change Price Target Change
Feb-22-24Upgrade The Benchmark Company Hold → Buy $9
Dec-05-23Initiated KeyBanc Capital Markets Overweight $6
Nov-06-23Downgrade The Benchmark Company Buy → Hold
Oct-13-23Resumed Piper Sandler Overweight $20
Feb-28-23Initiated Cowen Outperform
Dec-15-22Initiated Goldman Buy $30
Nov-16-22Initiated Truist Buy $29
Dec-21-21Initiated The Benchmark Company Buy $27
Nov-19-21Initiated Piper Sandler Overweight $33
Jan-05-21Initiated SVB Leerink Outperform $45
Feb-23-24 04:30PM
Feb-22-24 08:15PM
Feb-21-24 09:22AM
Feb-20-24 11:00PM
07:00PM Loading…
Jan-30-24 01:02PM
Jan-23-24 04:05PM
Jan-15-24 09:30AM
Jan-03-24 09:40AM
Dec-20-23 04:05PM
Dec-16-23 01:00PM
Dec-11-23 03:30PM
04:05PM Loading…
Nov-16-23 04:05PM
Nov-03-23 12:05PM
Nov-02-23 05:56PM
Nov-01-23 04:05PM
Oct-31-23 04:05PM
Oct-26-23 10:02AM
Oct-11-23 04:05PM
Sep-29-23 12:43PM
Sep-27-23 09:00AM
Sep-20-23 05:02PM
07:03PM Loading…
Sep-14-23 07:03PM
Sep-13-23 09:00AM
Aug-31-23 10:12PM
Aug-19-23 10:44AM
Aug-04-23 10:23AM
Aug-03-23 05:35PM
Jul-26-23 01:17PM
Jul-25-23 09:55AM
Jul-24-23 04:05PM
Jul-08-23 08:43PM
Jul-06-23 04:05PM
Jun-17-23 09:52AM
May-30-23 06:50AM
May-29-23 04:05PM
May-27-23 08:43AM
May-24-23 02:32PM
May-14-23 02:57PM
May-06-23 08:03AM
May-05-23 10:13AM
May-04-23 05:15PM
Apr-27-23 10:02AM
Apr-24-23 07:46PM
Apr-17-23 09:10AM
Apr-13-23 05:50AM
Apr-11-23 07:31PM
Apr-06-23 04:05PM
Apr-05-23 01:40PM
Mar-22-23 03:26PM
Mar-14-23 04:30PM
Mar-12-23 08:09AM
Feb-23-23 04:05PM
Feb-21-23 10:30PM
Feb-02-23 02:19PM
Feb-01-23 04:05PM
Jan-24-23 04:05PM
Jan-23-23 11:00AM
Jan-19-23 07:00PM
Jan-12-23 04:55AM
Jan-05-23 09:09AM
Jan-04-23 04:05PM
Dec-22-22 05:08AM
Dec-21-22 06:46AM
Dec-16-22 10:02AM
Dec-15-22 07:00AM
Dec-14-22 08:18AM
Dec-12-22 08:54AM
Dec-01-22 07:00AM
Nov-29-22 04:10PM
Nov-10-22 08:05AM
Nov-08-22 11:00PM
Nov-04-22 04:05PM
Nov-03-22 01:45PM
Nov-02-22 09:00AM
Nov-01-22 10:01AM
Oct-25-22 02:45PM
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Veronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hansen Carl L. G.Chief Executive OfficerMay 26Option Exercise2.7056,125151,538561,250May 30 01:14 PM
Thermopylae Holdings Ltd.10% OwnerMay 26Buy6.52153,000997,72856,012,493May 26 02:50 PM
Booth AndrewChief Financial OfficerMay 26Buy6.8514,50099,325153,000May 26 02:53 PM
Lecault VeroniqueChief Operating OfficerMay 05Option Exercise0.19250,00047,5002,020,122May 09 03:02 PM
Last Close
Feb 29 04:00PM ET
Dollar change
Percentage change
ETNB 89bio Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-2.00 Insider Own7.24% Shs Outstand90.77M Perf Week8.31%
Market Cap1.04B Forward P/E- EPS next Y-2.64 Insider Trans-0.82% Shs Float84.21M Perf Month12.56%
Income-126.56M PEG- EPS next Q-0.51 Inst Own103.87% Short Float12.56% Perf Quarter49.93%
Sales0.00M P/S- EPS this Y-15.85% Inst Trans8.90% Short Ratio7.71 Perf Half Y-33.24%
Book/sh5.42 P/B2.11 EPS next Y-13.79% ROA-38.31% Short Interest10.58M Perf Year-15.79%
Cash/sh4.94 P/C2.32 EPS next 5Y11.00% ROE-44.97% 52W Range6.57 - 22.93 Perf YTD2.69%
Dividend Est.- P/FCF- EPS past 5Y-25.73% ROI-29.10% 52W High-49.98% Beta0.96
Dividend TTM- Quick Ratio18.23 Sales past 5Y0.00% Gross Margin- 52W Low74.45% ATR (14)0.68
Dividend Ex-Date- Current Ratio18.23 EPS Y/Y TTM54.07% Oper. Margin0.00% RSI (14)62.23 Volatility6.69% 6.53%
Employees45 Debt/Eq0.06 Sales Y/Y TTM- Profit Margin- Recom1.40 Target Price30.67
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q19.81% Payout- Rel Volume0.94 Prev Close11.76
Sales Surprise- EPS Surprise-2.82% Sales Q/Q- EarningsFeb 29 AMC Avg Volume1.37M Price11.47
SMA2016.33% SMA508.89% SMA200-14.89% Trades Volume1,285,129 Change-2.47%
Date Action Analyst Rating Change Price Target Change
Jan-12-24Downgrade RBC Capital Mkts Outperform → Sector Perform $24 → $15
Oct-10-23Downgrade Oppenheimer Outperform → Perform
Aug-28-23Initiated UBS Buy $36
Jun-13-23Initiated Evercore ISI Outperform $49
May-12-22Upgrade Raymond James Outperform → Strong Buy $33 → $12
Dec-20-21Initiated H.C. Wainwright Buy $46
Oct-26-21Resumed Cantor Fitzgerald Overweight $49
Jul-29-21Resumed BTIG Research Buy $60
May-25-21Downgrade Raymond James Strong Buy → Outperform $65 → $35
Apr-21-21Initiated Cantor Fitzgerald Overweight $58
Today 04:05PM
Feb-22-24 03:55AM
Feb-06-24 04:05PM
Feb-05-24 04:05PM
Jan-18-24 09:35AM
09:55AM Loading…
Jan-10-24 09:55AM
Dec-19-23 04:05PM
Dec-12-23 07:30AM
Dec-07-23 07:00AM
Dec-06-23 04:36PM
Dec-04-23 07:00AM
Nov-27-23 08:00AM
Nov-21-23 04:01PM
Nov-12-23 12:15PM
Nov-09-23 07:28AM
04:01PM Loading…
Nov-08-23 04:01PM
Oct-17-23 08:00AM
Oct-11-23 03:49AM
Oct-10-23 04:13PM
Oct-03-23 04:05PM
Sep-21-23 08:00AM
Sep-20-23 08:00AM
Sep-05-23 08:00AM
Aug-09-23 04:01PM
Jul-12-23 04:30PM
Jul-07-23 09:40AM
Jun-24-23 05:05AM
Jun-07-23 04:05PM
08:00AM Loading…
May-29-23 09:35AM
May-23-23 08:00AM
May-13-23 08:53AM
May-05-23 09:55AM
May-04-23 04:05PM
May-02-23 08:00AM
Apr-29-23 08:25AM
Apr-13-23 09:55AM
Apr-02-23 08:27AM
Mar-24-23 10:57AM
Mar-22-23 04:16PM
Mar-21-23 05:10PM
Mar-15-23 09:55AM
Mar-10-23 08:00AM
Mar-04-23 01:30PM
Feb-21-23 08:00AM
Feb-08-23 08:00AM
Jan-24-23 09:28AM
Jan-22-23 09:21AM
Jan-04-23 04:01PM
Dec-12-22 06:30PM
Nov-25-22 04:04AM
Nov-10-22 04:05PM
Nov-05-22 01:00PM
Oct-13-22 08:00AM
Sep-26-22 09:21AM
Sep-07-22 08:00AM
Sep-01-22 10:17AM
Aug-26-22 08:05AM
Aug-18-22 08:00AM
Aug-15-22 08:23AM
Aug-11-22 08:00AM
Jul-11-22 02:15PM
Jul-05-22 08:05AM
Jun-29-22 01:47AM
Jun-28-22 04:02PM
Jun-21-22 08:00AM
Jun-02-22 10:57AM
May-11-22 04:05PM
May-03-22 08:00AM
Apr-26-22 08:00AM
Mar-25-22 08:35AM
Mar-24-22 04:05PM
Mar-01-22 04:03PM
Feb-24-22 08:00AM
Feb-09-22 08:00AM
Feb-03-22 04:30AM
Jan-25-22 07:58AM
Jan-24-22 04:05PM
Jan-05-22 04:54AM
Nov-14-21 06:30PM
Nov-11-21 04:05PM
Nov-03-21 08:00AM
Oct-25-21 04:05PM
Oct-04-21 09:29AM
Sep-21-21 08:00AM
Sep-08-21 04:15PM
Aug-12-21 04:05PM
Aug-03-21 04:15PM
Aug-02-21 08:30AM
Jul-09-21 06:22AM
89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PALEKAR ROHANChief Executive OfficerFeb 26Sale10.764,47748,173486,889Feb 28 06:43 PM
PALEKAR ROHANChief Executive OfficerDec 29Option Exercise1.9350,00096,500351,225Jan 03 04:54 PM
PALEKAR ROHANChief Executive OfficerDec 29Sale11.2050,000560,000301,225Jan 03 04:54 PM
LAPORTE KATHLEENDirectorJul 17Option Exercise2.6412,50033,00012,500Jul 18 06:04 PM
LAPORTE KATHLEENDirectorJul 17Sale18.8012,500235,0000Jul 18 06:04 PM
PALEKAR ROHANChief Executive OfficerJun 05Option Exercise1.9315,00028,950301,978Jun 07 05:04 PM
PALEKAR ROHANChief Executive OfficerJun 05Sale20.0015,000300,000286,978Jun 07 05:04 PM
Atkinson Edward Morrow IIIDirectorJun 01Option Exercise2.616,25016,3126,250Jun 05 05:03 PM
Atkinson Edward Morrow IIIDirectorJun 01Sale17.916,250111,9380Jun 05 05:03 PM
Le-Nguyen QuocSee RemarksMay 09Option Exercise3.1179,571247,466178,654May 11 05:01 PM
Le-Nguyen QuocSee RemarksMay 09Sale18.1113,683247,799164,971May 11 05:01 PM
Martins RyanChief Financial OfficerApr 04Sale14.958,721130,37953,578Apr 06 04:06 PM
Hayden Michael RDirectorMar 28Buy16.1561,538993,83961,538Mar 30 04:26 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 24Buy16.252,461,53839,999,99211,081,584Mar 30 05:00 PM
PALEKAR ROHANChief Executive OfficerMar 23Sale16.0015,000240,000269,080Mar 27 07:18 PM
Martins RyanChief Financial OfficerMar 23Sale16.115,00080,55053,578Mar 27 07:20 PM
Atkinson Edward Morrow IIIDirectorMar 01Option Exercise4.4410,00044,40010,000Mar 03 05:18 PM
Atkinson Edward Morrow IIIDirectorMar 01Sale13.6010,000136,0000Mar 03 05:18 PM